CHA Biotech Co., Ltd. (085660) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for CHA Biotech Co., Ltd. (085660:KRX), powered by AI.

Current Price
₩17,940
P/E Ratio
-135.1
Market Cap
1.7T
Sector
Healthcare
What is the CHA Biotech Co., Ltd. stock price forecast?

CHA Biotech Co., Ltd. is currently trading at ₩17,940. View real-time AI analysis on Alpha Lenz.

What is CHA Biotech Co., Ltd. insider trading activity?

View the latest insider trading data for CHA Biotech Co., Ltd. on Alpha Lenz.

What is CHA Biotech Co., Ltd.'s P/E ratio?

CHA Biotech Co., Ltd.'s P/E ratio is -135.1.

CHA Biotech Co., Ltd.

KRX · 085660
₩17,940
Ask about CHA Biotech Co., Ltd.'s future dividend policy...
Alpha Chat Insight

CHA Biotech Co., Ltd. trades at a P/E of -135.1 (undervalued) with modest ROE of -2.8%. 3Y revenue CAGR of 12.8% highlights clear growth momentum.

Ask for details

Company Overview

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare. In addition, the company develops immune cells, such as CBT101 for recurrent glioblastoma and solid cancer, and CBT111 and CAR-NK for solid cancer; and stem cells, including CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for macular degeneration and Stargardt's disease. Further, it offers IVF (fertility) services; cosmetics and cosmetic raw materials; medical devices and supplies; bioinsurance storage; research services; and other services. The company was founded in 2002 and is headquartered in Seoul, South Korea.

CEO최석윤
SectorHealthcare
IndustryBiotechnology
Employees278

Company Statistics

FY 2024

Profile

₩1,667,877,279,120Market Cap
₩1,045,049,021,120Revenue
92.97MShares Out
278Employees

Margins

26.34%Gross
3.22%EBITDA
-5.71%Operating
-0.59%Pre-Tax
-1.39%Net

Valuation

-135.06P/E
3.82P/B
1.04EV/Sales
62.84EV/EBITDA
-7.35P/FCF

Growth (CAGR)

12.83%Rev 3Yr
14.35%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-0.74%ROA
-2.85%ROE
1.58%ROIC

Financial Health

₩235,407,126,420Cash & Cash Equivalents
₩1,240,122,350,840Net Debt
205.26%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

CHA Biotech Co., Ltd. (ticker: 085660) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 278 employees. Market cap is $1.7T.

The current price is ₩17,940 with a P/E ratio of -135.06x and P/B of 3.82x.

ROE is -2.85% and operating margin is -5.71%. Annual revenue is $1.0T.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
CHA Biotech Co., Ltd. (Healthcare) Stock Forecast & Analysis ₩17,940 | Alpha Lenz